Barreleye, a medical AI company specializing in quantitative ultrasound imaging, announced on the 13th that it has secured a strategic Series A investment of approximately USD 10 million (KRW 14 billion) from a global leader in the healthcare industry. Prior to this round, the company attracted early-stage funding from investors including Mirae Science & Technology Holdings and K2 Ventures.

The participating global healthcare company is a market-leading innovator in medical imaging and diagnostics. Through this investment, the two companies plan to establish a long-term strategic collaboration for joint technology development and international market expansion.

Barreleye develops AI-driven diagnostic solutions based on deep learning and RF (radio-frequency) signal-based quantitative ultrasound technology, enabling the high-resolution detection of micro-structural tissue changes inside the human body.

The company is currently expanding its clinical applications across breast cancer, thyroid disease, liver disease, and cardiovascular conditions, while actively conducting joint research with major hospitals and global medical device manufacturers.

Hyunmin Bae, CEO of Barreleye and Professor at KAIST, stated, “This strategic investment validates that our AI-based quantitative ultrasound technology has reached a globally competitive, clinically viable level. We will accelerate global clinical adoption and regulatory submissions in partnership with our strategic investor.”

Founded in 2021, Barreleye is pioneering innovative diagnostic solutions that extract quantitative tissue information—previously available only through MRI—directly from ultrasound imaging. The company continues to lead the commercialization of medical imaging AI through collaborations with global medical device manufacturers and top-tier hospitals.

[출처] 머니투데이

'의료 AI' 배럴아이, 140억 시리즈A 투자유치 "해외진출 가속"